These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 33232911)

  • 21. Usp14 deficiency removes α-synuclein by regulating S100A8/A9 in Parkinson's disease.
    Ding L; Lu L; Zheng S; Zhang Z; Huang X; Ma R; Zhang M; Xu Z; Chen M; Guo Z; Zhu S; Gong J; Mao H; Zhang W; Xu P
    Cell Mol Life Sci; 2024 May; 81(1):232. PubMed ID: 38780644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models.
    Kelly R; Cairns AG; Ådén J; Almqvist F; Bemelmans AP; Brouillet E; Patton T; McKernan DP; Dowd E
    Biomolecules; 2021 Nov; 11(11):. PubMed ID: 34827685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
    St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
    J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
    Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
    Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protective mechanisms by glial cell line-derived neurotrophic factor and cerebral dopamine neurotrophic factor against the α-synuclein accumulation in Parkinson's disease.
    Er S; Airavaara M
    Biochem Soc Trans; 2023 Feb; 51(1):245-257. PubMed ID: 36794783
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.
    He Q; Koprich JB; Wang Y; Yu WB; Xiao BG; Brotchie JM; Wang J
    Mol Neurobiol; 2016 May; 53(4):2258-68. PubMed ID: 25972237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies.
    Hartlage-Rübsamen M; Bluhm A; Moceri S; Machner L; Köppen J; Schenk M; Hilbrich I; Holzer M; Weidenfeller M; Richter F; Coras R; Serrano GE; Beach TG; Schilling S; von Hörsten S; Xiang W; Schulze A; Roßner S
    Acta Neuropathol; 2021 Sep; 142(3):399-421. PubMed ID: 34309760
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Combined α-Synuclein/Fibril (SynFib) Model of Parkinson-Like Synucleinopathy Targeting the Nigrostriatal Dopamine System.
    Björklund A; Nilsson F; Mattsson B; Hoban DB; Parmar M
    J Parkinsons Dis; 2022; 12(8):2307-2320. PubMed ID: 36189605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Cinar E; Yalcin-Cakmakli G; Saka E; Ulusoy A; Yuruker S; Elibol B; Tel BC
    Exp Neurol; 2020 Aug; 330():113357. PubMed ID: 32437708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice.
    Oliveras-Salvá M; Macchi F; Coessens V; Deleersnijder A; Gérard M; Van der Perren A; Van den Haute C; Baekelandt V
    Neurobiol Aging; 2014 Nov; 35(11):2625-2636. PubMed ID: 25037286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha-synuclein pathology, microgliosis, and parvalbumin neuron loss in the amygdala associated with enhanced fear in the Thy1-aSyn model of Parkinson's disease.
    Torres ERS; Stanojlovic M; Zelikowsky M; Bonsberger J; Hean S; Mulligan C; Baldauf L; Fleming S; Masliah E; Chesselet MF; Fanselow MS; Richter F
    Neurobiol Dis; 2021 Oct; 158():105478. PubMed ID: 34390837
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
    Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
    Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Changes in α-Synuclein Posttranslational Modifications in an AAV-Based Mouse Model of Parkinson's Disease.
    Brembati V; Faustini G; Longhena F; Outeiro TF; Bellucci A
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intra-striatal infusion of the small molecule alpha-synuclein aggregator, FN075, does not enhance parkinsonism in a subclinical AAV-alpha-synuclein rat model.
    Patton T; Comini G; Narasimhan K; Cairns AG; Ådén J; Almqvist F; Bemelmans A; Brouillet E; McKernan DP; Dowd E
    Eur J Neurosci; 2024 Sep; 60(6):5234-5248. PubMed ID: 39143728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucocerebrosidase gene therapy prevents α-synucleinopathy of midbrain dopamine neurons.
    Rocha EM; Smith GA; Park E; Cao H; Brown E; Hayes MA; Beagan J; McLean JR; Izen SC; Perez-Torres E; Hallett PJ; Isacson O
    Neurobiol Dis; 2015 Oct; 82():495-503. PubMed ID: 26392287
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The α-Synuclein Origin and Connectome Model (SOC Model) of Parkinson's Disease: Explaining Motor Asymmetry, Non-Motor Phenotypes, and Cognitive Decline.
    Borghammer P
    J Parkinsons Dis; 2021; 11(2):455-474. PubMed ID: 33682732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease.
    Price DL; Koike MA; Khan A; Wrasidlo W; Rockenstein E; Masliah E; Bonhaus D
    Sci Rep; 2018 Nov; 8(1):16165. PubMed ID: 30385782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.